Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Disease must be clinically limited to the esophagogastric junction, defined TypeⅡ TypeⅢ(From the endoscopic point of view according to the AEG criteria)~2. Histologically confirmed primary adenocarcinoma~3. T2-4 N0-3 M0. T1 tumors are eligible if T1N1-3M0，~4. ECOG performance status ≦2~AEG is defined and described as tumors which have their center within 5cm proximal or distal of the anatomical cardia.~The classification of AEG type I, type II and type III AEG type I: adenocarcinoma of the distal esophagus,which usually arises from an area with specialized intestinal metaplasia of the esophagus, i Barrett's esophagus, and may infiltrate the esophago-gastric junction from above;~* AEG type II: true carcinoma of the cardia, arising from the cardia epithelium or short segments with intestinal metaplasia at the esophago-gastric junction;~* AEG type III: subcardial gastric carcinoma, which infiltrates the esophago-gastric junction and distal esophagus from below.~Exclusion Criteria:~1. Tis (in-situ carcinoma) and tumors determined to be TIN0 following endoscopy, endoscopic ultrasound and CT scanning.~2. Patients with primary carcinomas of the esophagus.~3. Prior chest or upper abdomen radiotherapy, prior systemic chemotherapy within the past 5 years, or prior esophageal or gastric surgery.~4. Patients with evidence of metastatic disease are not eligible.~5. Patients with a history of seizure disorder who are receiving phenytoin, phenobarbital, or other antiepileptic medication.~6. Patients who cannot fully comprehend the therapeutic implications of the protocol or comply with its requirements.~7. Patients with any medical or psychiatric condition or disease which, in the investigator's judgment, would make the patient inappropriate for entry into this study.~8. History of hypersensitivity to fluoropyrimidines, capecitabine, oxaliplatin or the ingredients of this product -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- postoperative chemotherapy,XELOX (Type: ACTIVE_COMPARATOR): None
- Preoperative Concurrent Chemoradiotherapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).